Status:
UNKNOWN
Evaluation of Optimal Ablation Index for Pulmonary Vein Isolation in Patients With AF Prospective Registry
Lead Sponsor:
Seoul National University Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
20-80 years
Brief Summary
In this study, the investigators identify the optimal AI value for achieving good acute outcomes in PVI. Through the Phase 1 study, the investigators will prospectively analyze data including ablatio...
Detailed Description
1. Phase 1 A total of 30 240 patients with AF will be prospectively and consecutively enrolled and applied conventional ablation strategy with AI-blinded using contact force sensing catheter (Thermoco...
Eligibility Criteria
Inclusion
- 20 to 80 years old
- Patients with symptomatic paroxysmal or persistent AF who had failed with anti-arrhythmic agents
Exclusion
- Patients who had previous ablation for AF
- Patients with left atrial (LA) diameter more than 50mm
- Inability or unwillingness to receive oral anticoagulation with a Vitamin K antagonist (VKA)or non-VKA (NOAC) agent
- Known severe left ventricular systolic function (ejection fraction\<35%)
- Pregnancy
Key Trial Info
Start Date :
January 23 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03389074
Start Date
January 23 2017
End Date
December 31 2020
Last Update
March 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National university Hostpital
Seoul, South Korea, 03080